During the follow-up period , in the intention-to-treat analysis , @ % of the patients receiving low-dose posaconazole and @ % receiving high-dose posaconazole , as compared with @ % receiving benznidazole , tested positive for T. cruzi DNA on rt-PCR assay ( P < @ for the comparison of the benznidazole group with either posaconazole group ) ; in the per-protocol analysis , @ % of the patients receiving low-dose posaconazole and @ % of those receiving high-dose posaconazole , as compared with @ % receiving benznidazole , tested positive on rt-PCR assay ( P < @ for the comparison of the benznidazole group with either posaconazole group ) .